Compare Kyndryl Holdings Inc (KD) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kyndryl Holdings Inc vs Medtronic PLC — how do they compare? Kyndryl Holdings Inc trades at $13.26 (market cap $2.97B), while Medtronic PLC trades at $90.58 (market cap $114.45B). The key difference: Medtronic PLC is far larger — about 38.5× Kyndryl Holdings Inc's market cap, and Medtronic PLC pays a 3.22% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals.
| KD | MDT | |
|---|---|---|
Market Cap | $2.97B | $114.45B |
Sector | Technology | Health |
52-Week High | $33.14 | $105.35 |
52-Week Low | $10.59 | $73.75 |
Enterprise Value | $5.79B | $133.19B |
Dividend Yield | — | 3.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kyndryl (KD) trades at $14.02, showing modest daily gains of 0.21%. The stock maintains a bullish technical signal with strong moving average support. Fundamentally, the company achieved profitability in 2025 with $252M net income after three years of losses, though revenue declined to $15.1B. Recent developments include the planned acquisition of Healthcare IT Leaders to boost AI capabilities and Q1 2027 results showing a $0.12 per share loss on $3.6B revenue.
While Kyndryl demonstrates improving profitability and strategic AI investments, investors face mixed signals with analyst consensus leaning hold (71%) and revenue declines. The stock trades near analyst targets with upside limited to technical momentum. Key risks include ongoing revenue pressure and the integration challenges of recent acquisitions.
Medtronic (MDT) trades at $87.16, up 1.44% today, with a bullish technical signal and consistent earnings beats. The company reported Q1 2026 EPS of $1.55, exceeding expectations, and maintains solid fundamentals with a 13.2% net income margin and $33.54B in revenue for 2025. Recent news highlights growth in cardiac ablation and the Hugo robotic platform, with management guiding for 11.75% organic revenue growth in Q1 2027.
The outlook is positive, supported by analyst consensus of a $98.75 price target and 60% buy ratings. Key opportunities include dividend stability and innovation in medical technology, while risks involve rising debt levels and competitive pressures. The stock's current valuation at a P/E of 23.37 offers moderate upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
